Form 4: Vaxcyte Director Carlos V. Paya Reports Share Transfers and Option Grants

Director Carlos V. Paya of Vaxcyte, Inc. reports the transfer of shares to a family trust and the grant of stock options.

Summary

• Carlos V. Paya, a director at Vaxcyte, Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 6, 2024, Mr. Paya transferred 2,500 shares of common stock to a family trust.
• Also on December 6, 2024, Mr. Paya was granted 2,500 shares of common stock.
• Additionally, on December 9, 2024, Mr. Paya transferred 7,250 stock options to a family trust.
• On the same day, Mr. Paya was granted 7,250 stock options.
• The stock options have an exercise price of $72.51 and will vest monthly, fully vesting by June 6, 2025, or the day before the next annual meeting of stockholders, subject to continuous service.
• The transactions involve the transfer of securities to a trust for the sole benefit of Mr. Paya.

Sentiment

Score: 7

Explanation: The document reflects standard transactions for a company director, indicating a neutral to slightly positive sentiment due to the continued alignment of the director's interests with the company's performance.

Future Outlook

The stock options and restricted stock units will vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a company director, which is common in the biotechnology industry where equity compensation is a significant part of executive pay.

Comparison to Industry Standards

• The vesting schedule of the stock options, with monthly vesting and full vesting by June 6, 2025, or the day before the next annual meeting, is typical for executive compensation packages in the biotech industry.
• The use of a family trust for holding securities is a common practice for estate planning and tax management among executives.
• The exercise price of $72.51 for the stock options is a standard practice, often set at or near the market price at the time of grant.

Stakeholder Impact

• The transactions do not have a direct impact on shareholders, employees, customers, suppliers, or creditors as they are related to internal director compensation and estate planning.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Share Transfer, Vaxcyte, Director, Carlos V. Paya, Family Trust, Equity Securities